![]() | |
Clinical data | |
---|---|
ATCvet code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H17FN6O3 |
Molar mass | 360.349 g·mol−1 |
3D model (JSmol) | |
| |
|
Atinvicitinib is a veterinary medicinal product under investigation for the treatment of atopic dermatitis in dogs. [1] Atinvicitinib is a selective Janus kinase (JAK) inhibitor, highly selective for Janus kinase 1 (JAK1). It inhibits the function of a variety of cytokines involved in itch and inflammation, as well as cytokines involved in allergy, that are dependent on JAK1 enzyme activity. [1] Reduction of allergy mediated inflammation, which is dependent on JAK1 enzyme activity, leads to a reduction of inflammation associated white blood cell counts (within the reference range). [1]
In June 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Numelvi, tablets, intended for dogs. [1] The applicant for this veterinary medicinal product is Intervet International B.V. [1]
Atinvicitinib is the international nonproprietary name. [2]